AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Oxford Biomedica PLC

Remuneration Information Nov 8, 2016

5190_dirs_2016-11-08_e021ffde-421b-47fe-94e4-05551e2cfb0c.html

Remuneration Information

Open in Viewer

Opens in native device viewer

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 6769O

Oxford Biomedica PLC

08 November 2016

8 November 2016

Oncimmune Holdings plc

("Oncimmune" or the "Company")

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PDMR AND PERSONS CLOSELY ASSOCIATED WITH THEM

Oncimmune Holdings plc (AIM: ONC.L), a leading early cancer detection company developing and commercialising its proprietary EarlyCDT® platform technology, today announces that on 8 November 2016, options over ordinary shares of the Company were awarded to certain Directors and certain PDMRs under the Company's 2016 Share Option Plan (an amalgamation of the Company's 2005 and 2007 Share Option Plans) as follows.

Name Position Number of share options awarded Option exercise price per share (pence) Percentage of issued share capital (%)
Meinhard Schmidt Non-executive Chairman 120,370 108 0.236
Geoffrey Hamilton-Fairley Chief Executive Officer 528,273 1 1.035
119,875 108 0.235
Andrew Millet Chief Financial Officer 92,593 108 0.181
Andrea Murray Chief Operational Scientist 41,667 108 0.082
Maarten Brusse Chief Commercial Officer 74,074 108 0.145

The options are subject to the rules of the 2016 Share Option Plan and vest in five equal annual parts, the first fifth vesting on 7 November 2017 and each year thereafter for a further four years, subject to continued employment. Unless otherwise indicated in the table above, the options are exercisable at 108 pence, being the mid-market closing price of the Company's ordinary shares on 7 November 2016

For further information:

Oncimmune Holdings plc

Geoffrey Hamilton-Fairley, Chief Executive Officer

[email protected]

Zeus Capital Limited (Nominated Adviser and Broker)

Phil Walker, Giles Balleny, Dominic Wilson

+44 (0) 203 829 5000

Media enquiries:

Consilium Strategic Communications

Chris Gardner, Mary-Jane Elliott, Matthew Neal, Lindsey Neville

[email protected]

+44 (0) 20 3709 5708

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Meinhard Schmidt

2

Reason for the notification

a)

Position/status

Non-Executive Chairman, Director

b)

Initial notification/Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Oncimmune Holdings plc

b)

LEI

N/A

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

options over 1p ordinary shares - 2016 Share Option Plan

ISIN GB00BYQ94H38

b)

Nature of the transaction

Grant of options over ordinary shares

c)

Price(s) and volume(s)

Price(s) Volume(s)
N/A 120,370

d)

Aggregated information

Price(s) Volume(s)
N/A 120,370

e)

Date of the transaction

8 November 2016

f)

Place of the transaction

N/A

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Geoffrey Hamilton-Fairley

2

Reason for the notification

a)

Position/status

Chief Executive Officer

b)

Initial notification/Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Oncimmune Holdings Plc

b)

LEI

N/A

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

options over 1p ordinary shares - 2016 Share Option Plan

ISIN GB00BYQ94H38

b)

Nature of the transaction

Grant of options over ordinary shares

c)

Price(s) and volume(s)

Price(s) Volume(s)
N/A 528,273
N/A 119.875

d)

Aggregated information

Price(s) Volume(s)
N/A 648,148

e)

Date of the transaction

8 November 2016

f)

Place of the transaction

N/A

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Andrew Millet

2

Reason for the notification

a)

Position/status

Chief Financial Officer

b)

Initial notification/Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Oncimmune Holdings Plc

b)

LEI

N/A

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

options over 1p ordinary shares - 2016 Share Option Plan

ISIN GB00BYQ94H38

b)

Nature of the transaction

Grant of options over ordinary shares

c)

Price(s) and volume(s)

Price(s) Volume(s)
N/A 92,593

d)

Aggregated information

Price(s) Volume(s)
N/A 92,593

e)

Date of the transaction

8 November 2016

f)

Place of the transaction

N/A

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Andrea Murray

2

Reason for the notification

a)

Position/status

Chief Operational Scientist and PDMR

b)

Initial notification/Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Oncimmune Holdings Plc

b)

LEI

N/A

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

options over 1p ordinary shares - 2016 Share Option Plan

ISIN GB00BYQ94H38

b)

Nature of the transaction

Grant of options over ordinary shares

c)

Price(s) and volume(s)

Price(s) Volume(s)
N/A 41,667

d)

Aggregated information

Price(s) Volume(s)
N/A 41,667

e)

Date of the transaction

8 November 2016

f)

Place of the transaction

N/A

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Maarten Brusse

2

Reason for the notification

a)

Position/status

Chief Commercial Officer and PDMR

b)

Initial notification/Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Oncimmune Holdings Plc

b)

LEI

N/A

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

options over 1p ordinary shares - 2016 Share Option Plan

ISIN GB00BYQ94H38

b)

Nature of the transaction

Grant of options over ordinary shares

c)

Price(s) and volume(s)

Price(s) Volume(s)
N/A 74,074

d)

Aggregated information

Price(s) Volume(s)
N/A 74,074

e)

Date of the transaction

8 November 2016

f)

Place of the transaction

N/A

This information is provided by RNS

The company news service from the London Stock Exchange

END

DSHBIBDBGBGBGLI

Talk to a Data Expert

Have a question? We'll get back to you promptly.